Neoadjuvant therapy in breast cancer – objectives and tasks

Skrócona strona pozycji
dc.contributor.authorOstańska, Elżbieta
dc.contributor.authorBartusik-Aebisher, Dorota
dc.contributor.authorAebisher, David
dc.contributor.authorKaznowska, Ewa
dc.date.accessioned2019-07-16T07:16:16Z
dc.date.available2019-07-16T07:16:16Z
dc.date.issued2019
dc.descriptionDorota Bartusik-Aebisher acknowledges support from the National Center of Science NCN (New drug delivery systems-MRI study, Grant OPUS-13 number 2017/25/B/ST4/02481).pl_PL.UTF-8
dc.description.abstractIntroduction. Neoadiuvant therapy (NCT) in the treatment of breast cancer is employed for patients with early stage disease or with inoperable disease. NCT can decrease the tumor volume. It can facilitate breast conservation therapy. Response to NCT is a strong predictor of outcome breast cancer (BC). Direct target therapies has markedly improved the result of treatment BC. Aim. Therapy for breast cancer continues to improve. The importance of tumor burden on local control rates will be in the future. Material and methods. This analysis was performed using a systematic literature search. Results. The latest scientific reports give hope for greater safety and a better life for patients based on optimized and effective therapy. Conclusion. Currently, improving the effectiveness of breast cancer treatment is mainly related to the optimal use of classic therapeutic strategies. New classes of substances have been approved for treatment or are in advanced stages of clinical development.pl_PL.UTF-8
dc.identifier.citationEuropean Journal of Clinical and Experimental Medicine T. 17, z. 2 (2019), s. 153–156pl_PL.UTF-8
dc.identifier.doi10.15584/ejcem.2019.2.8
dc.identifier.eissn2544-1361
dc.identifier.issn2544-2406
dc.identifier.urihttp://repozytorium.ur.edu.pl/handle/item/4759
dc.language.isoengpl_PL.UTF-8
dc.publisherWydawnictwo Uniwersytetu Rzeszowskiegopl_PL.UTF-8
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectneoadjuvant therapy (NCT)pl_PL.UTF-8
dc.subjectbreast cancer (BC)pl_PL.UTF-8
dc.subjecttriple negative breast cancer (TNBC)pl_PL.UTF-8
dc.titleNeoadjuvant therapy in breast cancer – objectives and taskspl_PL.UTF-8
dc.typereviewpl_PL.UTF-8
Pliki
Oryginalny pakiet
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
8 ostańska-neoadjuvant therapy.pdf
Rozmiar:
114.26 KB
Format:
Adobe Portable Document Format
Opis:
Pobierz
Pakiet licencji
Aktualnie wyświetlane 1 - 1 z 1
Obrazek miniatury
Nazwa:
license.txt
Rozmiar:
1.22 KB
Format:
Item-specific license agreed upon to submission
Opis:
Pobierz
Kolekcje
European Journal of Clinical and Experimental Medicine T.17, z. 2 (2019)